Similar Search Results

Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia

Cremieux, Pierre-Yves; Finkelstein, Stan N.; Berndt, … - In: PharmacoEconomics 16 (1999) 5, pp. 459-472

unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing … literature review and from 3 US clinical trials involving more than 4500 patients with cancer who were treated with chemotherapy …, radiotherapy, epoetin and blood transfusions as needed under standard care for patients with cancer. Main outcome measures and …

Persistent link: https://www.econbiz.de/10005405014

Pricing in the market for anticancer drugs

Howard, David H.; Bach, Peter B.; Berndt, Ernst R.; … - In: The journal of economic perspectives : EP ; a journal … 29 (2015) 1, pp. 139-162

Persistent link: https://www.econbiz.de/10011409439

Specialty drug prices and utilization after loss of us patent exclusivity, 2001-2007

Conti, Rena M.; Berndt, Ernst R. - In: Measuring and modeling health care costs, (pp. 273-321). 2018

Persistent link: https://www.econbiz.de/10011812702

Pricing in the market for anticancer drugs

Howard, David H.; Bach, Peter B.; Berndt, Ernst R.; … - 2015

Persistent link: https://www.econbiz.de/10010485559

Specialty drug prices and utilization after loss of US patent exclusivity, 2001 - 2007

Conti, Rena M.; Berndt, Ernst R. - 2014

Persistent link: https://www.econbiz.de/10010352001

Pricing in the Market for Anticancer Drugs

Howard, David H. - 2015

Drugs like bevacizumab ($50,000 per treatment episode) and ipilimumab ($120,000 per episode) have fueled the perception that the launch prices of anticancer drugs are increasing over time. Using an original dataset of 58 anticancer drugs approved between 1995 and 2013, we find that launch...

Persistent link: https://www.econbiz.de/10013030058

Pricing in the Market for Anticancer Drugs

Howard, David H. - 2015

Persistent link: https://www.econbiz.de/10012457799

Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007

Conti, Rena M. - 2014

2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally …

Persistent link: https://www.econbiz.de/10012458648

Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001-2007

Conti, Rena - 2014

2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally …

Persistent link: https://www.econbiz.de/10013056202